Sign In
Buy BIVI
$1.65
-0.0500 (-2.94%)
At Close: Jun 03, 2026
BioVie: Quick Rise And Fall Of An Alzheimer's Disease Drug Developer
06:43am, Monday, 20'th Feb 2023
BioVie came out with phase 2 data in December. BIVI stock went up a lot, then fell equally badly, after that.
BioVie Inc: A Catalyst-Rich Year Ahead
12:04am, Monday, 16'th Jan 2023
BioVie's pipeline indications represent a combined addressable market size of more than $100 billion with high unmet medical needs. Phase 2 trials have provided evidence to indicate that NE3107 may im
Why Shares of BioVie Rose 15.3% in December
01:07pm, Thursday, 05'th Jan 2023
The biotech announced positive news from a pair of phase 2 clinical trials.
BioVie: 9 Reasons For Enthusiasm
11:26pm, Wednesday, 21'st Dec 2022
Over the past few months, BioVie has reported good data from a Phase 2 trial in Alzheimer's and a Phase 2 placebo-controlled Parkinson's disease trial. The Phase 3 trial in Alzheimer's is ongoing.
Here's Why Momentum in BioVie Inc. (BIVI) Should Keep going
10:32am, Friday, 09'th Dec 2022
If you are looking for stocks that are well positioned to maintain their recent uptrend, BioVie Inc. (BIVI) could be a great choice. It is one of the several stocks that passed through our "Recent Pri
Why BioVie Stock Is Soaring Today
12:01pm, Thursday, 08'th Dec 2022
The more investors learned about BioVie's latest clinical results, the more they liked.
BioVie updates investors on its Alzheimer's and Parkinson's clinical programs
09:08am, Wednesday, 07'th Dec 2022
BioVie Inc (NASDAQ:BIVI) said it has made significant progress with its clinical programs, including its drug candidate NE3107 showing a clinically meaningful increase in motor control in patients wit
Why BioVie's Shares Tumbled Tuesday
01:54pm, Tuesday, 06'th Dec 2022
The clinical-stage biotech released data on its prospective Alzheimer's therapy.
BioVie: Treating Alzheimer's, Parkinson's, And Potentially Reversing The Biological Clock
12:00pm, Tuesday, 06'th Dec 2022
BioVie's NE3107 has now shown improvement of cognition and function on different Alzheimer's rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo
BioVie Inc (NASDAQ:BIVI) has announced positive results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease (PD) and Alzheimer's Disease (AD). The NM201 study (NCT05083260) is
Are Medical Stocks Lagging BioVie (BIVI) This Year?
11:17am, Friday, 25'th Nov 2022
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of
Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?
11:17am, Wednesday, 09'th Nov 2022
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
Trading Ideas On The Upcoming CTAD 2022 Conference
03:27pm, Wednesday, 02'nd Nov 2022
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie
BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022
08:00am, Monday, 24'th Oct 2022
CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of
